GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug - GSK ( NYSE:GSK )
Friday, GSK plc GSK released the headline results of the MATINEE Phase 3 trial evaluating Nucala ( mepolizumab ) , a monoclonal antibody that targets interleukin-5 ( IL-5 ) in adults with chronic obstructive pulmonary disease ( COPD ) , or smoker's lungs.
| Ticker |
Sentiment |
Impact |
|
GSK
|
Neutral
|
32 %
|
|
VRNA
|
Somewhat Bullish
|
22 %
|
